KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$127.0 million.

  • Vir Biotechnology's Net Cash Flow fell 14036.26% to -$127.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.1 million, marking a year-over-year increase of 5910.3%. This contributed to the annual value of $57.4 million for FY2024, which is 10946.19% up from last year.
  • According to the latest figures from Q3 2025, Vir Biotechnology's Net Cash Flow is -$127.0 million, which was down 14036.26% from -$61.7 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Net Cash Flow high stood at $690.9 million for Q2 2022, and its period low was -$542.7 million during Q3 2022.
  • In the last 5 years, Vir Biotechnology's Net Cash Flow had a median value of -$52.8 million in 2024 and averaged -$14.3 million.
  • Examining YoY changes over the last 5 years, Vir Biotechnology's Net Cash Flow showed a top increase of 45244.19% in 2022 and a maximum decrease of 181603.88% in 2022.
  • Vir Biotechnology's Net Cash Flow (Quarter) stood at -$364.2 million in 2021, then surged by 68.15% to -$116.0 million in 2022, then plummeted by 81.95% to -$211.1 million in 2023, then skyrocketed by 125.76% to $54.4 million in 2024, then tumbled by 333.65% to -$127.0 million in 2025.
  • Its last three reported values are -$127.0 million in Q3 2025, -$61.7 million for Q2 2025, and $49.3 million during Q1 2025.